AMA announces new CPT code for Johnson & Johnson’s COVID-19 vaccine

January 25, 2021
Medicare Web

The American Medical Association (AMA) recently added a new CPT code that will be used to report a COVID-19 vaccine candidate under development by Janssen Pharmaceutica, a division of Johnson & Johnson.

The new CPT code is:

  • 91303, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use

The AMA also created a new HCPCS Level II code for the vaccine’s administration:

  • 0031A, immunization administration by intramuscular injection of SARS-CoV-2 (COVID-19) vaccine, DNA, spike protein, Ad26 vector, preservative free, 5x1010 viral particles/0.5 mL dosage, single dose

These codes will go into effect when the Food and Drug Administration approves the vaccine candidate or grants it emergency use authorization, according to the AMA.

A complete list of CPT/HCPCS codes for COVID-19 vaccines and associated payment allowances is available here